A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack

More Data To Be Reported At CTAD In November

 
• By Mandy Jackson

Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.

Wolf pack with alpha and full moon concept
Lecanemab is the first of three near-term anti-amyloid readouts • Source: Shutterstock

More from Clinical Trials

More from R&D